API SUPPLIERS

API Suppliers

0

US DMFs Filed

0

CEP/COS Certifications

0

JDMFs Filed

0

EU WC

0

Listed Suppliers

0

API REF. PRICE (USD / KG)

0

API Market Place

0

INTERMEDIATES

0

DOSSIERS // FDF

USA (Orange Book)

0

Europe

0

Canada

0

Australia

0

South Africa

0

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

FDF Market Place

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

17

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Also known as: Brilaroxazine, 1239729-06-6, X8l60ba01i, 6-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2h-benzo[b][1,4]oxazin-3(4h)-one, 2h-1,4-benzoxazin-3(4h)-one, 6-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butoxy)-, 2h-1,4-benzoxazin-3(4h)-one, 6-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-

Molecular Formula

C₂₂H₂₅Cl₂N₃O₃

Molecular Weight

450.4 g/mol

InChI Key

PMKMNTBZJOXTJW-UHFFFAOYSA-N

FDA UNII

X8L60BA01I

Brilaroxazine (RP5063) is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective disorder. Reviva Pharmaceuticals also intends to investigate RP5063 for the treatment of bipolar disorder, major depressive disorder, psychosis/agitation associated with Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder (ADD/ADHD), and autism. As of May 2015, it is in phase III clinical trials for schizophrenia.

1 2D Structure

Brilaroxazine

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

6-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-4H-1,4-benzoxazin-3-one

2.1.2 InChI

InChI=1S/C22H25Cl2N3O3/c23-17-4-3-5-19(22(17)24)27-11-9-26(10-12-27)8-1-2-13-29-16-6-7-20-18(14-16)25-21(28)15-30-20/h3-7,14H,1-2,8-13,15H2,(H,25,28)

2.1.3 InChI Key

PMKMNTBZJOXTJW-UHFFFAOYSA-N

2.1.4 Canonical SMILES

C1CN(CCN1CCCCOC2=CC3=C(C=C2)OCC(=O)N3)C4=C(C(=CC=C4)Cl)Cl

2.2 Other Identifiers

2.2.1 UNII

X8L60BA01I

2.3 Synonyms

2.3.1 Depositor-Supplied Synonyms

1. Brilaroxazine

2. 1239729-06-6

3. X8l60ba01i

4. 6-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2h-benzo[b][1,4]oxazin-3(4h)-one

5. 2h-1,4-benzoxazin-3(4h)-one, 6-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butoxy)-

6. 2h-1,4-benzoxazin-3(4h)-one, 6-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-

7. 6-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2h-benzo(b)(1,4)oxazin-3(4h)-one

8. Brilaroxazin

9. Brilaroxazine [inn]

10. Unii-x8l60ba01i

11. Brilaroxazine [who-dd]

12. Schembl3404085

13. Bdbm312188

14. Dtxsid001136921

15. Db09226

16. Rp-5063

17. Us9604944, 15b (example 14)

18. Hy-109112

19. Cs-0077721

20. 6-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-2h-1,4-benzoxazin-3(4h)-one

21. 6-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-4h-1,4-benzoxazin-3-one

22. 2036070-48-9

2.4 Create Date

2010-09-07

3 Chemical and Physical Properties

Molecular Formula	C₂₂H₂₅Cl₂N₃O₃
Molecular Weight	450.4 g/mol
XLogP3	4.4
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	5
Rotatable Bond Count	7
Exact Mass	449.1272971 g/mol
Monoisotopic Mass	449.1272971 g/mol
Topological Polar Surface Area	54 Å²
Heavy Atom Count	30
Formal Charge	0
Complexity	562
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1